Gianni Di Lecce

Dr. Gianni Di Lecce

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Brigida BarberioBrigida Barberio
Brigida Barberio
BVBeatrice Varotto
Beatrice Varotto
MDMatteo D'Angelo
Matteo D'Angelo
LTLara Tessari
Lara Tessari
GLGianni Di Lecce
Gianni Di Lecce
GTGiulia Tognana
Giulia Tognana
Short bowel syndrome (SBS) is the leading cause of chronic intestinal failure in adults, arising when the residual small bowel can no longer absorb the macronutrients, water and electrolytes needed to sustain health without intravenous supplementation. Its management is, at its core, a nutritional problem. This review synthesises current evidence and guideline recommendations on the two pillars of that management: dietary (oral/enteral) therapy and parenteral nutritional support. We frame both around the two variables that dominate clinical behaviour, namely residual intestinal anatomy and the phase of intestinal adaptation, and translate them into anatomy-tailored dietary strategies, rational fluid and electrolyte replacement, micronutrient surveillance, and the composition, delivery and complications of (home) parenteral nutrition. We also position the pharmacological adjuncts, culminating in glucagon-like peptide-2 (GLP-2) analogues, within a stepwise strategy to reduce parenteral-support dependence. The goal throughout is a practical, physiology-anchored approach that maximises enteral autonomy and quality of life while preventing the metabolic, hepatic and catheter-related complications of long-term intravenous feeding.

18 September 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
TATarek Arraf
Tarek Arraf
JCJavier Chahuan
Javier Chahuan
Luisa BertinLuisa Bertin
Luisa Bertin
GLGianni Di Lecce
Gianni Di Lecce
ESEmma Sirinic
Emma Sirinic
ESEdoardo Vincenzo Savarino
Edoardo Vincenzo Savarino
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated, non-IgE-mediated food allergy and a leading cause of dysphagia and food impaction in adults, with rising prevalence worldwide. Diagnosis requires ≥15 eosinophils per high-power field on esophageal biopsy after exclusion of other causes of gastrointestinal eosinophilia. Food allergens, principally milk, wheat, eggs, legumes and seafood, drive the inflammatory process, and treatment options include proton pump inhibitors, topical corticosteroids, biologic agents and endoscopic dilation for stricturing disease. Among these, dietary therapy is the only approach that removes the causative trigger rather than suppressing the inflammatory response, making drug-free, sustained remission achievable. Elemental diets achieve the highest histological remission rates but are poorly tolerated in practice; empiric elimination following a step-up strategy, starting with one or two foods and escalating in the absence of response, is more practical for most adults. Conventional allergy testing cannot reliably identify food triggers in EoE and is not recommended for this purpose. Reintroduction of the trigger food leads to relapse, making long-term adherence essential, and not all patients are suitable candidates: repeated endoscopy, dietary restriction, quality of life impact and the risk of avoidant restrictive food intake disorder (ARFID) are barriers that must be weighed before recommending this approach. This review summarizes the available dietary approaches in adult and adolescent EoE, covering empiric elimination strategies and their efficacy, allergy test-directed diets, patient selection, the role of diet alongside other treatments, and nutritional adequacy and adherence.

2 October 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
Brigida BarberioBrigida Barberio
Brigida Barberio
BVBeatrice Varotto
Beatrice Varotto
MDMatteo D'Angelo
Matteo D'Angelo
LTLara Tessari
Lara Tessari
GLGianni Di Lecce
Gianni Di Lecce
GTGiulia Tognana
Giulia Tognana
Short bowel syndrome (SBS) is the leading cause of chronic intestinal failure in adults, arising when the residual small bowel can no longer absorb the macronutrients, water, and electrolytes needed to sustain health without intravenous supplementation. Its management is, at its core, a nutritional problem. This narrative review summarises and critically appraises current evidence and guideline recommendations on the two pillars of that management: dietary (oral/enteral) therapy and parenteral nutritional support. We frame both around the two variables that dominate clinical behaviour, namely residual intestinal anatomy and the phase of intestinal adaptation, and translate them into anatomy-tailored dietary strategies, rational fluid and electrolyte replacement, micronutrient surveillance, and the composition, delivery, and complications of (home) parenteral nutrition. We also position the pharmacological adjuncts, culminating in glucagon-like peptide-2 (GLP-2) analogues, within a stepwise strategy to reduce parenteral support dependence. The goal throughout is a practical, physiology-anchored approach that maximises enteral autonomy and quality of life while preventing the metabolic, hepatic and catheter-related complications of long-term intravenous feeding. The literature was identified through structured but non-systematic searches of PubMed/MEDLINE, Embase and the Cochrane Library, and the nature of the evidence supporting each recommendation, ranging from randomised trials to expert consensus, is indicated throughout the text.